-
公开(公告)号：KR101135636B1
公开(公告)日：2012-04-17
申请号：KR1020090102458
申请日：2009-10-27
Applicant: 서울대학교산학협력단
IPC: C12N5/074 , A61K35/545
CPC classification number: C12N5/0662 , A61K35/48 , C12N2500/38 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/155 , C12N2501/165 , C12N2501/39 , C12N2506/02
Abstract: Provided is a method for producing mesenchymal stem cells from human pluripotent stem cells, the method including: a) forming embryonic bodies from human pluripotent stem cells; b) attaching the embryonic bodies to a culture dish to induce natural differentiation of the embryonic bodies into mesenchymal stem cells; and c) performing continuous proliferative culturing of the mesenchymal stem cells while still maintaining the identity of the mesenchymal stem cells. Also, provided is a standardized method for inducing differentiation of mesenchymal stem cells, which can be broadly applied to all human pluripotent stem cells regardless of a difference in the genetic background thereof. Ultimately, the present invention can continuously mass-produces the mesenchymal stem cells necessary for regenerative medicine and cell therapy by using human pluripotent stem cells, thereby realizing practical uses of cell therapy products, and further the present invention is expected to highly contribute to treatments of incurable diseases, such as cardiovascular diseases and neurological disorders.
-
公开(公告)号：KR102037823B1
公开(公告)日：2019-10-29
申请号：KR1020130094832
申请日：2013-08-09
Applicant: 서울대학교산학협력단
IPC: C07K14/475 , C12P21/00 , A61K38/18
-
公开(公告)号：KR101757530B1
公开(公告)日：2017-07-13
申请号：KR1020150063203
申请日：2015-05-06
Applicant: 서울대학교산학협력단
IPC: A61K38/17 , C12N5/0789 , C07K14/705
CPC classification number: A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
Abstract: 본발명은조혈모세포의세포주기를조절하는 KAI1 단백질및 이의용도에관한것으로서, 보다구체적으로는 KAI1(CD82) 폴리펩타이드또는이를코딩하는유전자를포함하는조혈모세포의세포주기조절용조성물, 또는혈액종양예방또는치료용약학적조성물에관한것이다. 본발명에따르면, KAI1(CD82)이조혈모세포의 Hierarchy 중가장최상위의조혈모세포(LT-HSC)에만발현하고, 상기 KAI1을이용하여 LT-HSC를순도높게얻을수 있는바, LT-HSC만을순도높게이식함으로써조혈모세포이식의다양한부작용을억제할 수있다. 또한, KAI1이 LT-HSC의 Quiescence(정지)에중요하게작용하며, LT-HSC의 Quiescence을유지함으로써다양한 Stress(5-FU, Irradiation)에의한세포손상에대해저항성을가지는바, 상기세포를이용하여세포뱅크를만들고세포이식을통한혈액종양세포치료제로사용될수 있을것으로기대된다.
-
24.发明授权CD31-ITIM 폴리펩타이드 또는 그 유전자를 포함하는 만성염증성 질환 또는 자가면역질환 치료 또는 예방용 약학 조성물 有权CD31-ITIM包含CD31-ITIM多肽或编码其的核酸的药物组合物，用于治疗或预防慢性炎性疾病或自身免疫疾病
公开(公告)号：KR101592082B1
公开(公告)日：2016-02-04
申请号：KR1020140007149
申请日：2014-01-21
Applicant: 서울대학교산학협력단
Abstract: 본원은 CD31-ITIM 폴리펩타이드또는그 유전자를포함하는염증반응과관련된사이토카인조절용약학조성물을개시한다. 본원에따른조성물은항염증성사이토카인및/또는염증성사이토카인의분비를조절하여, 만성염증과관련된다양한질환또는자가면역질환을포함하는면역질환의예방또는치료에유용하게사용될수 있다.
-
公开(公告)号：KR1020150035875A
公开(公告)日：2015-04-07
申请号：KR1020150025886
申请日：2015-02-24
Applicant: 서울대학교산학협력단
IPC: C12N5/0775 , C12N5/0789 , A61K35/28 , A61K35/12
CPC classification number: A61K35/28 , A61K2035/124 , C12N5/0634 , C12N5/0647 , C12N2501/14 , C12N2501/22 , C12N2506/11 , C12N5/0662
Abstract: 본원은 EPO 또는 APS-프라이밍을통해혈관생성능이향상된말초혈액줄기세포의제조방법및 그용도를개시한다. 본원의방법에따라제조된세포는혈관생성을유도하여, 혈관생성의촉진이필요한다양한질환예를들면근육, 뇌, 심장, 신장, 또는대장에서발생한허혈성질환, 예를들면허혈로인한조직손상, 뇌경색, 뇌졸중, 재관류손상, 심근경색, 울혈성심장기능상실, 말초혈관폐색증, 심장비후, 저심장수축증, 저심장이완증, 부적응성심장비대, 수축기심부전, 이완기심부전, 고혈압성심부전, 동맥및 승포판질환, 폐동맥판질환심혈관, 또는허혈성장심혈관재생또는회복에유용하게사용될수 있다.
Abstract translation: 公开了一种通过EPO或APS引发具有增强的血管发生能力及其用途的外周血干细胞的制备方法。 根据本发明产生的细胞诱导血管生成，并且可以有利地用于治疗需要促进血管生成的各种疾病，例如肌肉，脑，心脏，肾脏或大肠中的缺血; 例如缺血 - 触发的组织损伤，脑梗塞，中风，再灌注损伤，心肌梗死，充血性心力衰竭，周围血管阻塞，心脏肥大，收缩期，舒张期，失调的心律失常，收缩期心力衰竭，舒张性心力衰竭，高血压心力衰竭 ，动脉和二尖瓣疾病，肺部疾病，心血管疾病或缺血性心血管疾病。
-
Patent Agency Ranking
公开(公告)号：KR1020150018203A
公开(公告)日：2015-02-23
申请号：KR1020130094832
申请日：2013-08-09
Applicant: 서울대학교산학협력단
IPC: C07K14/475 , C07K1/14 , C12N5/0775 , C12N5/0735
Abstract: The present invention relates to a method for mass-producing angiogenesis factors using stem cell aggregates and a composition for treating and preventing ischemic diseases including culture medium of the stem cell aggregates. More specifically, in the present invention, stem cell aggregates are made in a buffer solution, which has less stability and less fetal bovine serum derived from animals and a non-additive basal medium, which has no antibiotics to increase tolerance via a suspension culture, thereby mass-producing angiogenesis factors from the stem cell aggregate culture medium while the survival rate of the angiogenesis factor remarkably increases, when transplanted to ischemic tissues, compared with that of transplanted single cells, so the composition of the present invention can be used for efficiently treating or preventing ischemic diseases.
Abstract translation: 本发明涉及使用干细胞聚集体大规模生产血管生成因子的方法和用于治疗和预防包括干细胞聚集体的培养基的缺血性疾病的组合物。 更具体地说，在本发明中，干细胞聚集体制成缓冲溶液，该缓冲溶液具有较少的稳定性和较少的来自动物的胎牛血清和非添加剂的基础培养基，该培养基没有抗生素通过悬浮培养增加耐受性， 从而与移植的单细胞相比，干细胞聚集培养基的血管生成因子大量生成，同时血管生成因子的存活率显着增加，移植到缺血组织中，因此本发明的组合物可以有效地使用 治疗或预防缺血性疾病。
-
公开(公告)号：KR1020140021154A
公开(公告)日：2014-02-20
申请号：KR1020120086957
申请日：2012-08-08
Applicant: 서울대학교산학협력단
IPC: A61K35/14 , A61K35/15 , C12N5/0786
CPC classification number: A61K35/14 , A61K35/15 , C12N5/0645 , C12N2513/00
Abstract: The present invention provides a pharmaceutical composition for treating ischemic diseases containing human blood derived hematosphere. Specifically the present invention induces vascular smooth muscle cells and vascular endothelial cells through effective three-dimensional culture using mononuclear cells of blood, and ultimately can be applied for the development of a new cell treatment agent for treating the ischemic diseases through effective angiogenesis.
Abstract translation: 本发明提供了一种用于治疗含有人血源性血球的缺血性疾病的药物组合物。 具体地说，本发明通过使用血液的单核细胞的有效的三维培养来诱导血管平滑肌细胞和血管内皮细胞，最终可用于开发新的细胞治疗剂，以通过有效的血管生成治疗缺血性疾病。
-
公开(公告)号：KR1020140021153A
公开(公告)日：2014-02-20
申请号：KR1020120086956
申请日：2012-08-08
Applicant: 서울대학교산학협력단
Abstract: The present invention relates to a technology in which only trace amounts of adult stem cells and progenitor cells present in the blood are effectively cultured and proliferated by using blood mononuclear cells, thereby differentiating inflammatory mononuclear cells into anti-inflammatory mononuclear cells and efficiently securing masses of anti-inflammatory Type 2 helper lymphocytes and regulatory lymphocytes, and a method for treating immune-related diseases using the technology. The anti-inflammatory mononuclear cells, Type 2 helper lymphocytes, and regulatory lymphocytes according to the present invention are immune cells derived from patients, and thus can greatly contribute to the development of cell therapeutic agents for autoimmune diseases.
Abstract translation: 本发明涉及通过使用血液单核细胞有效地培养和增殖存在于血液中的微量成体干细胞和祖细胞的技术，从而将炎症性单核细胞分化成抗炎单核细胞，有效地确保 抗炎2型辅助淋巴细胞和调节性淋巴细胞，以及使用该技术治疗免疫相关疾病的方法。 根据本发明的抗炎单核细胞，2型辅助淋巴细胞和调节性淋巴细胞是来自患者的免疫细胞，因此可大大有助于自身免疫性疾病的细胞治疗剂的发展。
-
公开(公告)号：KR1020130085383A
公开(公告)日：2013-07-29
申请号：KR1020130005902
申请日：2013-01-18
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: A pharmaceutical composition for treatment of metabolic diseases including a blood-born hemosphere (BBHS) is provided to be able to be used as medicine for metabolic diseases by inducing differentiation of BBHS to an insulin-secreting cell. CONSTITUTION: A pharmaceutical composition for treatment of metabolic diseases includes BBHS. The BBHS is formed by isolating monocytic cells from human blood and performing the three dimensional aggregation cultivation. The BBHS is induced to an insulin-secreting cell. The metabolic diseases are selected from a group consisting of diabetes, hyperlipidemia, and obesity. A method of curing metabolic diseases administers the pharmaceutically effective dose of the pharmaceutical composition to an individual.
Abstract translation: 目的：提供一种用于治疗包括血液生成气体（BBHS）在内的代谢疾病的药物组合物，通过诱导BBHS分泌到胰岛素分泌细胞，能够用作代谢疾病的药物。 构成：用于治疗代谢疾病的药物组合物包括BBHS。 BBHS通过从人血液中分离单核细胞并进行三维聚集培养而形成。 BBHS被诱导到胰岛素分泌细胞。 代谢疾病选自糖尿病，高脂血症和肥胖症。 治疗代谢疾病的方法将药物组合物的药学有效剂量给予个体。
-
公开(公告)号：KR1020100116812A
公开(公告)日：2010-11-02
申请号：KR1020090035421
申请日：2009-04-23
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: A method for inducing and culturing cardiac stem cells using cell aggregation is provided to extract obtain a large amount of stem cells. CONSTITUTION: A method for inducing and culturing cardiac stem cells using cell aggregation comprises: a step of isolating differentiation cells from heart; a step of culturing cells in a three-dimensional structure; a step of proliferating cells and culturing organ; and a step of culturing and storing for a long time and thawing again to obtain secondary cardiac sphere.
Abstract translation: 目的：提供使用细胞聚集诱导和培养心脏干细胞的方法，以提取获得大量的干细胞。 构成：使用细胞聚集诱导和培养心脏干细胞的方法包括：从心脏分离分化细胞的步骤; 以三维结构培养细胞的步骤; 增殖细胞和培养器官的一个步骤; 以及长时间培养和储存并再次解冻以获得二次心脏球的步骤。
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.031 seconds)
